Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06769659 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
A Phase 2 study of Epilepsy, Generalized and Epilepsy, Absence, sponsored by NeuroPro Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06769659 is a Phase 2 study of Epilepsy, Generalized and Epilepsy, Absence that is actively recruiting participants, run by NeuroPro Therapeutics. The registered enrollment target is 10 participants, below the 120-participant average among 3 other Epilepsy, Generalized trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06769659, a Phase 2 study of Epilepsy, Generalized and Epilepsy, Absence, is actively recruiting participants, sponsored by NeuroPro Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 80 mg BID orally or matching placebo BID in each of two treatment periods.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG NPT 2042
Study Locations (1)
Arkansas
- Clinical Trials, Inc. (CTI) - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2026-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06769659
The ClinicalTrials.gov registry entry for NCT06769659 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 3 other Epilepsy, Generalized trials with a reported enrollment target (92% lower). The listed sponsor is NeuroPro Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Epilepsy, Generalized appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06769659 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT06769659 about?
NCT06769659 is a clinical study titled "A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures". This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 80...
What is the current status of trial NCT06769659?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-03-11. Estimated completion is 2026-05-30.
What conditions does trial NCT06769659 study?
This clinical trial studies the following conditions: Epilepsy, Generalized, Epilepsy, Absence.
What interventions are being tested in trial NCT06769659?
The interventions under investigation include: Placebo (OTHER), NPT 2042 (DRUG).
Who is sponsoring clinical trial NCT06769659?
This trial is sponsored by NeuroPro Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06769659 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Generalized
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.